Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma

British Journal of Haematology

Volumn 159, Issue 3, 2012, Pages 322-328

  Else, Monica ^a   Marín Niebla, Ana ^a,b   de la Cruz, Fátima ^b   Batty, Paul ^a   Ríos, Eduardo ^c   Dearden, Claire E ^a   Catovsky, Daniel ^a   Matutes, Estella ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Chemotherapy; Rituximab; Splenectomy; Splenic marginal zone lymphoma; Toxicity

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; ASPERGILLOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFECTION; MALE; MALIGNANT TRANSFORMATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84867477542     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12036     Document Type: Article

References (23)

1. Arcaini, L., Orlandi, E., Scotti, M., Brusamolino, E., Passamonti, F., Burcheri, S., Colombo, N., Vanelli, L., Sbalzarini, G. & Lazzarino, M. (2004) Combination of rituximab, cyclophosphamide and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clinical Lymphoma, 4, 250-252.
2. Bennett, M., Sharma, K., Yegena, S., Gavish, I., Dave, H.P. & Schechter, G.P. (2005) Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica, 90, 856-858.
3. Brown, J.R., Friedberg, J.W., Feng, Y., Scofield, S., Phillips, K., Dal Cin, P., Joyce, R., Takvorian, R.W., Fisher, D.C., Fisher, R.I., Liesveld, J., Marquis, D., Neuberg, D. & Freedman, A.S. (2009) A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. British Journal of Haematology, 145, 741-748.
4. Dungarwalla, M., Appiah-Cubi, S., Kulkarni, S., Saso, R., Wotherspoon, A., Osuji, N., Swansbury, J., Cunningham, D.C., Catovsky, D., Dearden, C.E. & Matutes, E. (2008) High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. British Journal of Haematology, 143, 71-74.
5. Else, M., Dearden, C.E., Matutes, E., Forconi, F., Lauria, F., Ahmad, H., Kelly, S., Liyanage, A., Ratnayake, V., Shankari, J., Whalley, I. & Catovsky, D. (2011) Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leukemia & Lymphoma, 52(Suppl. 2), 75-78.
6. Fabbri, A., Gozzetti, A., Lazzi, S., Lenoci, M., D'Amuri, A., Leoncini, L. & Lauria, F. (2006) Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clinical Lymphoma & Myeloma, 6, 496-499.
7. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jäger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H., Stilgenbauer, S. & International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
8. Isaacson, P.G., Piris, M.A., Berger, F., Swerdlow, S.H., Thieblemont, C., Pittaluga, S. & Harris, N.L. (2008) Splenic B-cell marginal zone lymphoma. In: WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues (eds byS.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman), pp. 185-187. IARC Press, Lyon.
9. James, D.F. & Kipps, T.J. (2011) Rituximab in chronic lymphocytic leukemia. Advances in Therapy, 28, 534-554.
10. Kalpadakis, C., Pangalis, G.A., Dimopoulou, M.N., Vassilakopoulos, T.P., Kyrtsonis, M.C., Korkolopoulou, P., Kontopidou, F.N., Siakantaris, M.P., Dimitriadou, E.M., Kokoris, S.I., Tsaftaridis, P., Plata, E. & Angelopoulou, M.K. (2007) Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematological Oncology, 25, 127-131.
11. Lefrère, F., Lévy, V., François, S., Delarue, R., Ifrah, N., Tilly, H., Valensi, F., Troussard, X., Varet, B. & Hermine, O. (2004) Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update. Leukemia, 18, 1924-1925.
12. Matutes, E. (2007) Splenic marginal zone with and without villous lymphocytes. Current Treatment Options in Oncology, 8, 109-116.
13. Matutes, E., Oscier, D., Montalban, C., Berger, F., Callet-Bauchu, E., Dogan, A., Felman, P., Franco, V., Iannitto, E., Mollejo, M., Papadaki, T., Remstein, E.D., Salar, A., Solé, F., Stamatopoulos, K., Thieblemont, C., Traverse-Glehen, A., Wotherspoon, A., Coiffier, B. & Piris, M.A. (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia, 22, 487-495.
14. Parry-Jones, N., Matutes, E., Gruszka-Westwood, A.M., Swansbury, G.J., Wotherspoon, A.C. & Catovsky, D. (2003) Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. British Journal of Haematology, 120, 759-764.
15. Robak, T., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B.V., Larratt, L., Geisler, C.H., Montillo, M., Zyuzgin, I., Ganly, P.S., Dartigeas, C., Rosta, A., Maurer, J., Mendila, M., Saville, M.W., Valente, N., Wenger, M.K. & Moiseev, S.I. (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1756-1765.
16. Schulz, H., Bohlius, J., Skoetz, N., Trelle, S., Kober, T., Reiser, M., Dreyling, M., Herold, M., Schwarzer, G., Hallek, M. & Engert, A. (2007) Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database of Systematic Reviews, 17, CD003805.
17. Siddhartha, G. & Vijay, P. (2009) R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. Journal of Hematology & Oncology, 2, 14.
18. Thieblemont, C., Felman, P., Callet-Bauchu, E., Traverse-Glehen, A., Salles, G., Berger, F. & Coiffier, B. (2003) Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. The Lancet Oncology, 4, 95-103.
19. Thomas, D.A., O'Brien, S., Cortes, J., Faderl, S., Fayad, L., Garcia-Manero, G., Wierda, W., Verstovsek, S., Kornblau, S., Pierce, S., Kantarjian, H. & Keating, M. (2001) Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphomas (MZL) with single agent rituximab. Blood, 98(Suppl. 1), 134a (Abstract 563).
20. Troussard, X., Valensi, F., Duchayne, E., Garand, R., Felman, P., Tulliez, M., Henry-Amar, M., Bryon, P.A. & Flandrin, G. (1996) Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hématologie Cellulaire (GFHC). British Journal of Haematology, 93, 731-736.
21. Tsimberidou, A.M., Catovsky, D., Schlette, E., O'Brien, S., Wierda, W.G., Kantarjian, H., Garcia-Manero, G., Wen, S., Do, K.A., Lerner, S. & Keating, M.J. (2006) Outcomes in patients with splenic marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer, 107, 125-135.
22. Vidal, L., Gafter-Gvili, A., Salles, G., Dreyling, M.H., Ghielmini, M., Hsu Schmitz, S.F., Pettengell, R., Witzens-Harig, M. & Shpilberg, O. (2011) Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. Journal of the National Cancer Institute, 103, 1799-1806.
23. Woyach, J.A., Ruppert, A.S., Heerema, N.A., Peterson, B.L., Gribben, J.G., Morrison, V.A., Rai, K.R., Larson, R.A. & Byrd, J.C. (2011) Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB Study 9712. Journal of Clinical Oncology, 29, 1349-1355.